imatinib has been researched along with Granulocytic Leukemia, Chronic in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " A pharmacokinetic study revealed that 18a had over 4 h of half-life and 24% bioavailability in rats." | 1.43 | Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le ( Chen, C; Hu, Z; Liang, X; Liu, J; Liu, Q; Liu, X; Lv, F; Qi, S; Qi, Z; Wang, A; Wang, B; Wang, L; Wang, W; Zhang, S; Zhao, Z; Zou, F, 2016) |
| " Further modification led to orally bioavailable dual MNK1 and 2 and BCR-ABL1 inhibitors 53 and 54, which are efficacious in a mouse xenograft model and also reduce the level of phosphorylated eukaryotic translation initiation factor 4E in the tumor tissues." | 1.43 | Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. ( Cherian, J; Chew, YS; Choong, ML; Ding, LJ; Guo, S; Hill, J; Ho, M; Jeyaraj, DA; Joy, JK; Keller, TH; Kwek, ZP; Lee, MA; Lim, S; Liu, B; Manoharan, V; Nacro, K; Ong, EH; Ong, ST; Pendharkar, V; Poh, ZY; Poulsen, A; Sangthongpitag, K; Wee, JL; Wong, YX; Yang, HY, 2016) |
| " It also displays good pharmacokinetics properties with an oral bioavailability of 35." | 1.42 | Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. ( Ding, K; Lu, X; Luo, J; Pan, X; Ren, X; Wang, D; Yu, R; Zhang, Z; Zhuang, X, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Adrián, FJ | 1 |
| Ding, Q | 1 |
| Sim, T | 1 |
| Velentza, A | 1 |
| Sloan, C | 1 |
| Liu, Y | 1 |
| Zhang, G | 1 |
| Hur, W | 1 |
| Ding, S | 1 |
| Manley, P | 1 |
| Mestan, J | 2 |
| Fabbro, D | 2 |
| Gray, NS | 1 |
| Silvestri, R | 1 |
| Marfè, G | 1 |
| Artico, M | 1 |
| La Regina, G | 1 |
| Lavecchia, A | 1 |
| Novellino, E | 1 |
| Morgante, E | 1 |
| Morgante, M | 1 |
| Di Stefano, C | 1 |
| Catalano, G | 1 |
| Filomeni, G | 1 |
| Abruzzese, E | 1 |
| Ciriolo, MR | 1 |
| Russo, MA | 1 |
| Amadori, S | 1 |
| Cirilli, R | 1 |
| La Torre, F | 1 |
| Sinibaldi Salimei, P | 1 |
| Bradner, JE | 1 |
| Xu, F | 1 |
| Shi, X | 1 |
| Li, S | 1 |
| Cui, J | 1 |
| Lu, Z | 1 |
| Jin, Y | 1 |
| Lin, Y | 1 |
| Pang, J | 1 |
| Pan, J | 1 |
| Crespan, E | 1 |
| Radi, M | 1 |
| Zanoli, S | 1 |
| Schenone, S | 1 |
| Botta, M | 1 |
| Maga, G | 1 |
| Manley, PW | 2 |
| Stiefl, N | 1 |
| Cowan-Jacob, SW | 2 |
| Kaufman, S | 1 |
| Wartmann, M | 1 |
| Wiesmann, M | 1 |
| Woodman, R | 1 |
| Gallagher, N | 1 |
| Li, Y | 2 |
| Shen, M | 1 |
| Zhang, Z | 3 |
| Luo, J | 2 |
| Pan, X | 3 |
| Lu, X | 2 |
| Long, H | 1 |
| Wen, D | 1 |
| Zhang, F | 1 |
| Leng, F | 1 |
| Tu, Z | 1 |
| Ren, X | 2 |
| Ding, K | 3 |
| Richters, A | 1 |
| Ketzer, J | 2 |
| Getlik, M | 1 |
| Grütter, C | 1 |
| Schneider, R | 1 |
| Heuckmann, JM | 1 |
| Heynck, S | 1 |
| Sos, ML | 1 |
| Gupta, A | 1 |
| Unger, A | 1 |
| Schultz-Fademrecht, C | 1 |
| Thomas, RK | 1 |
| Bauer, S | 2 |
| Rauh, D | 2 |
| Wang, D | 1 |
| Zhuang, X | 1 |
| Yu, R | 1 |
| Muthyala, R | 1 |
| Shin, WS | 1 |
| Xie, J | 1 |
| Sham, YY | 1 |
| Liu, X | 4 |
| Kung, A | 1 |
| Malinoski, B | 1 |
| Prakash, GK | 1 |
| Zhang, C | 1 |
| Liang, X | 1 |
| Wang, B | 2 |
| Zou, F | 1 |
| Wang, A | 2 |
| Qi, S | 1 |
| Chen, C | 2 |
| Zhao, Z | 1 |
| Wang, W | 4 |
| Qi, Z | 1 |
| Lv, F | 1 |
| Hu, Z | 2 |
| Wang, L | 2 |
| Zhang, S | 1 |
| Liu, Q | 3 |
| Liu, J | 2 |
| Sang, F | 1 |
| Ding, Y | 1 |
| Wang, J | 3 |
| Sun, B | 1 |
| Sun, J | 2 |
| Geng, Y | 1 |
| Wu, LL | 1 |
| Liu, JW | 1 |
| Bai, C | 1 |
| Yang, G | 1 |
| Zhang, Q | 2 |
| Li, LY | 1 |
| Chen, Y | 1 |
| Cherian, J | 1 |
| Nacro, K | 1 |
| Poh, ZY | 1 |
| Guo, S | 1 |
| Jeyaraj, DA | 1 |
| Wong, YX | 1 |
| Ho, M | 1 |
| Yang, HY | 1 |
| Joy, JK | 1 |
| Kwek, ZP | 1 |
| Liu, B | 1 |
| Wee, JL | 1 |
| Ong, EH | 1 |
| Choong, ML | 1 |
| Poulsen, A | 1 |
| Lee, MA | 1 |
| Pendharkar, V | 1 |
| Ding, LJ | 1 |
| Manoharan, V | 1 |
| Chew, YS | 1 |
| Sangthongpitag, K | 1 |
| Lim, S | 1 |
| Ong, ST | 1 |
| Hill, J | 1 |
| Keller, TH | 1 |
| Millet, A | 1 |
| Plaisant, M | 1 |
| Ronco, C | 1 |
| Cerezo, M | 1 |
| Abbe, P | 1 |
| Jaune, E | 1 |
| Cavazza, E | 1 |
| Rocchi, S | 1 |
| Benhida, R | 2 |
| Kaitsiotou, H | 1 |
| Keul, M | 1 |
| Hardick, J | 1 |
| Mühlenberg, T | 1 |
| Ehrt, C | 1 |
| Krüll, J | 1 |
| Medda, F | 1 |
| Koch, O | 1 |
| Giordanetto, F | 1 |
| Marzag, H | 1 |
| Zerhouni, M | 1 |
| Tachallait, H | 1 |
| Demange, L | 1 |
| Robert, G | 1 |
| Bougrin, K | 1 |
| Auberger, P | 1 |
| Schoepfer, J | 1 |
| Jahnke, W | 1 |
| Berellini, G | 1 |
| Buonamici, S | 1 |
| Cotesta, S | 1 |
| Dodd, S | 1 |
| Drueckes, P | 1 |
| Gabriel, T | 1 |
| Groell, JM | 1 |
| Grotzfeld, RM | 1 |
| Hassan, AQ | 1 |
| Henry, C | 1 |
| Iyer, V | 1 |
| Jones, D | 1 |
| Lombardo, F | 1 |
| Loo, A | 1 |
| Pellé, X | 1 |
| Rummel, G | 1 |
| Salem, B | 1 |
| Warmuth, M | 1 |
| Wylie, AA | 1 |
| Zoller, T | 1 |
| Marzinzik, AL | 1 |
| Furet, P | 1 |
| Sorrenti, V | 1 |
| Pittalà, V | 1 |
| Romeo, G | 1 |
| Amata, E | 1 |
| Dichiara, M | 1 |
| Marrazzo, A | 1 |
| Turnaturi, R | 1 |
| Prezzavento, O | 1 |
| Barbagallo, I | 1 |
| Vanella, L | 1 |
| Rescifina, A | 1 |
| Floresta, G | 1 |
| Tibullo, D | 1 |
| Di Raimondo, F | 1 |
| Intagliata, S | 1 |
| Salerno, L | 1 |
| Jiang, Z | 1 |
| Hu, C | 1 |
| Wu, H | 1 |
| Zhang, Y | 1 |
| Huang, T | 1 |
| Ren, T | 1 |
| Li, L | 1 |
| Xia, R | 1 |
| Ge, J | 1 |
| Li, W | 1 |
| Chu, J | 1 |
| Fan, T | 1 |
| Zhang, W | 1 |
| Yao, M | 1 |
| Ning, Z | 1 |
| Wang, M | 1 |
| Zhao, X | 1 |
| Wen, A | 1 |
| Liang, L | 1 |
| Sun, Y | 1 |
| Si, R | 1 |
| Fu, J | 1 |
| Zhang, J | 2 |
| Schoepf, AM | 1 |
| Salcher, S | 1 |
| Obexer, P | 1 |
| Gust, R | 1 |
| El-Damasy, AK | 1 |
| Jin, H | 1 |
| Seo, SH | 1 |
| Bang, EK | 1 |
| Keum, G | 1 |
| Pan, YL | 1 |
| Zeng, SX | 1 |
| Hao, RR | 1 |
| Liang, MH | 1 |
| Shen, ZR | 1 |
| Huang, WH | 1 |
| Pandrala, M | 1 |
| Bruyneel, AAN | 1 |
| Hnatiuk, AP | 1 |
| Mercola, M | 1 |
| Malhotra, SV | 1 |
| Marín-Rubio, JL | 1 |
| Peltier-Heap, RE | 1 |
| Dueñas, ME | 1 |
| Heunis, T | 1 |
| Dannoura, A | 1 |
| Inns, J | 1 |
| Scott, J | 1 |
| Simpson, AJ | 1 |
| Blair, HJ | 1 |
| Heidenreich, O | 1 |
| Allan, JM | 1 |
| Watt, JE | 1 |
| Martin, MP | 1 |
| Saxty, B | 1 |
| Trost, M | 1 |
1 review available for imatinib and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imat | 2022 |
26 other studies available for imatinib and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line; Cell Line, Transformed; Cell Proli | 2006 |
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Caspase 3; Caspase 8; Caspase 9; Ca | 2006 |
A pulse at the heart of targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Hum | 2009 |
Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Cell | 2010 |
Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms.
Topics: Adenosine Triphosphate; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Kinetics; | 2010 |
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.
Topics: Benzamides; Cell Line; Cell Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, | 2010 |
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Design; D | 2012 |
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.
Topics: Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; Humans; Leukemia, | 2013 |
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
Topics: Cell Proliferation; Fusion Proteins, bcr-abl; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mode | 2015 |
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response | 2015 |
Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.
Topics: Alkynes; Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Fusi | 2015 |
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell | 2016 |
Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resista | 2016 |
Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Chemistry Techniques, | 2016 |
Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screen | 2016 |
Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.
Topics: Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-A | 2017 |
Modular synthesis of new C-aryl-nucleosides and their anti-CML activity.
Topics: Antineoplastic Agents; Catalysis; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Me | 2018 |
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Topics: Allosteric Regulation; Animals; Dogs; Drug Discovery; Fusion Proteins, bcr-abl; Humans; Leukemia, My | 2018 |
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-a | 2018 |
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants includi
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferat | 2018 |
Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1,3,4-thiadiazol- 2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway.
Topics: Antineoplastic Agents; Drug Design; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosph | 2019 |
Discovery of novel Bcr-Abl
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Proliferation; Drug Design; Fusion Proteins, | 2019 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistan | 2020 |
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Topics: Amination; Antineoplastic Agents; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; | 2020 |
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous | 2022 |
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.
Topics: Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammat | 2022 |